A randomized controlled study of pergolide in patients with restless legs syndrome

Neurology

Volumn 52, Issue 5, 1999, Pages 944-950

  Wetter, Thomas C ^a   Stiasny, K ^c   Winkelmann, J ^a   Buhlinger, A ^a   Brandenburg, U ^c   Penzel, T ^c   Medori, R ^b   Rubin, M ^b   Oertel, W H ^c   Trenkwalder, C ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOMPERIDONE; PERGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SLEEP DISORDER;

EID: 0033596810     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.5.944     Document Type: Article

References (35)

1. Walters AS, International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-642.
2. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lésperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12: 61-65.
3. Coleman R. Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: Guilleminault C, ed. Sleeping and waking disorders: indications and techniques. Menlo Park, CA: Addison-Wesley, 1982:265-295.
4. Pollmächer T, Schulz H. Periodic leg movements (PLM): their relationship to sleep stages. Sleep 1993;16:572-577.
5. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996;47:1435-1441.
6. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-1848.
7. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind crossover trial. Sleep 1995;18:681-688.
8. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind, randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-458.
9. Barley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996; 19:801-810.
10. Silber MH, Shepard JW, Wisbey JA. Pergolide in the management of restless legs syndrome: an extended study. Sleep 1997;20:878-882.
11. Winkelmann J, Wetter TC, Stiasny K, Oertel WH, Trenkwalder C. Treatment of restless legs syndrome with pergolide: an open clinical trial. Mov Disord 1998;13:566-569.
12. Jasper HH. The 10-20 electrode system of the International Federation. Electroencephalogr Clin Neurophysiol 1958;10: 371-375.
13. Rechtschaffen A, Kales A, eds. A manual of standardized terminology, technique and scoring system for sleep stages of human subjects. Los Angeles: Brain Information Service/ Brain Research Institute, UCLA, 1968.
14. Lauer CJ, Riemann D, Wiegand M, Berger M. From early to late adulthood: changes in EEG sleep of depressed patients and healthy volunteers. Biol Psychiatry 1991;29:979-993.
15. Atlas Task Force of the American Sleep Disorders Association, Guilleminault C, chairman. Recording and scoring leg movements. Sleep 1993;16:748-759.
16. Atlas Task Force of the American Sleep Disorders Association, Guilleminault C, chairman. EEG arousals: scoring rules and examples. Sleep 1992;15:173-184.
17. Goertelmeyer R. On the development of a standardized sleep inventory for the assessment of sleep. In: Kubicki S, Herrmann WM, eds. Methods of sleep research. Stuttgart: Gustav Fischer, 1985:93-98.
18. Kramer C, Kerekjarto M, Leplow B, Krasemann EO. Lebensqualitätsmessungen im wöchentlich erhobenen Verlauf bei Herzinfarktpatienten. Psychother Psychosom Med Psychol 1990;40:409-416.
19. National Institute of Mental Health. 12-CGI: clinical global impressions. In: Guy W, Bonato RR, eds. Manual for the EC-DEU assessment battery. 2nd ed. Chevy Chase, Maryland: National Institute of Mental Health, 1970:1-6.
20. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087.
21. Lehmacher W. Analysis of the crossover design in the presence of residual effects. Stat Med 1991;10:891-899.
22. Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling experimentwise error rate. Biometrics 1991;47:511-521.
23. Staedt J, Wassmuth F, Ziemann U, Hajak G, Rüther E, Stoppe G. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-dopa. J Neural Transm 1997;104:461-468.
24. Allen RP, Barley CJ, Hening WA, Walters AS, Yaffee J, Wagner ML. Pergolide treatment of the restless legs syndrome: a double-blind placebo-controlled study with objective assessment of leg movements. Neurology 1998;50(suppl 4):A68. Abstract.
25. Monti JM, Hawkins M, Jantos H, D'Angelo L, Fernández M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology 1988;95: 395-400.
26. Cianchetti C, Masala C, Mangoni A, Gessa GL. Suppression of REM and delta sleep by apomorphine in man: a dopamine mimetic effect. Psychopharmacology 1980;67:61-65.
27. Wyatt RJ, Chase TN, Scott J, Snyder F, Engleman K. Effect of L-dopa on the sleep of man. Nature 1970;228:999-1001.
28. Gillin JC, Post RM, Wyatt RJ, Goodwin FK, Snyder F, Bunney WE Jr. REM inhibitory effect of L-DOPA infusion during human sleep. Electroencephalogr Clin Neurophysiol 1973;35: 181-186.
29. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981;32:337-362.
30. Markham A, Benfield P. Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease. CNS Drugs 1997;7:328-340.
31. Lemberger L, Crabtree R, Callaghan JT. Pergolide: a potent long-acting dopamine-receptor agonist. Clin Pharmacol Ther 1980;27:642-651.
32. Trenkwalder C, Hening WA, Walters AS, Campbell S, Rahman K, Chokroverty S. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord 1999;14:102-110.
33. Walker SL, Fine A, Kryger MH. L-dopa/carbidopa for nocturnal movement disorder in uremia. Sleep 1996;19:214-218.
34. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43: 445.
35. Allen RP, Barley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.